Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-22), DocCheck AG's 9-Day RSI is 53.78.
The industry rank for DocCheck AG's 9-Day RSI or its related term are showing as below:
HAM:AJ91's 9-Day RSI is ranked better than 73.96% of 699
companies
in the Healthcare Providers & Services industry
Industry Median: 48.3
vs HAM:AJ91: 53.78
DocCheck AG (HAM:AJ91) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
DocCheck AG 9-Day RSI Related Terms
HAM:AJ91 vs VEEV, BTSG, TEM: 9-Day RSI Comparison
For the Health Information Services subindustry, DocCheck AG's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocCheck AG 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocCheck AG's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where DocCheck AG's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DocCheck AG (HAM:AJ91) has a 9-Day RSI of 53.78 as of Jul. 22, 2026. According to the industry distribution chart, DocCheck AG ranks #182 out of 699 companies in the Healthcare Providers & Services industry, placing it in the top 26%.
Is DocCheck AG's 9-Day RSI too high?
DocCheck AG's current 9-Day RSI is 53.78. The Healthcare Providers & Services industry median 9-Day RSI is 48.30. DocCheck AG's value of 53.78 is 11.3% above this industry median. Based on the distribution chart, DocCheck AG ranks #182 out of 699 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, DocCheck AG has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does DocCheck AG's 9-Day RSI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DocCheck AG ranks #182 out of 699 companies for 9-Day RSI. This puts DocCheck AG in the upper half of its industry. The industry median 9-Day RSI is 48.30. DocCheck AG's value of 53.78 is 11.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 48.30, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DocCheck AG's current 9-Day RSI of 53.78 is 11.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 48.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocCheck AG's current 9-Day RSI is 53.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocCheck AG stock overvalued right now?
DocCheck AG (HAM:AJ91) has a current 9-Day RSI of 53.78. The stock's GF Value™ is €9.52, compared to a current price of €11.90 — trading 25% above its estimated fair value. The current 9-Day RSI is 53.78 and 11.3% above the Healthcare Providers & Services industry median of 48.30. DocCheck AG's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For DocCheck AG (HAM:AJ91), the current 9-Day RSI is 53.78 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocCheck AG (HAM:AJ91) Overvalued in 2026?
Based on GuruFocus' analysis, DocCheck AG stock appears to be overvalued.
The current stock price of €11.90 is trading 25% above its estimated GF Value™ of €9.52.
Key valuation signals for HAM:AJ91:
9-Day RSI: 53.78
GF Value™: €9.52 vs. price of €11.90 (25% above fair value)
Industry Position: 11.3% above the Healthcare Providers & Services median (#182 of 699)
No single metric tells the full story. See the HAM:AJ91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocCheck AG is a Germany-based company engaged in the healthcare sector. It operates through subsidiaries: antwerpes AG develops integrated communication concepts for the healthcare sector, including social media and digital communication with focus on e-marketing concepts, search engine optimization (SEO), search engine advertising (SEA) and search engine marketing (SEM); DocCheck Medical Services GmbH operates an online platform for healthcare professionals, such as physicians and pharmacists; DocCheck Medizinbedarf und Logistik GmbH wholesales medical products from third parties and also produces own medical products, and DocCheck Guano AG is a venture capital company with focus on e-health companies and promotes healthcare startups.
71GF Score
Get the complete analysis for HAM:AJ91
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:AJ91 has been successfully added to your 
